

THE ACTION OF TWO METABOLITES OF VITAMIN D<sub>3</sub>;  
25,26-DIHYDROXYCHOLECALCIFEROL (25,26(OH)<sub>2</sub>D<sub>3</sub>) AND  
24,25-DIHYDROXYCHOLECALCIFEROL (24,25(OH)<sub>2</sub>D<sub>3</sub>) ON BONE RESORPTION

M. PEACOCK and G. A. TAYLOR

*M.R.C. Mineral Metabolism Unit, The General Infirmary, Leeds, LS1 3EX, England*

and

J. REDEL

*Institut de Rhumatologie - Centre de Recherches sur les Maladies Ostéo-Articulaires (U. 5 INSERM, ERA 377 CNRS) -  
Hôpital Cochin, 27 rue du Fg. St. Jacques, 75674 Paris Cédex 14, France*

Received 9 January 1976

## 1. Introduction

In addition to the well known active metabolites of vitamin D<sub>3</sub>, 25-OHD<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub>, two other dihydroxy derivatives of cholecalciferol have been isolated [1,2] from biological sources and identified [1-3] as 24,25- and 25,26(OH)<sub>2</sub>D<sub>3</sub>. Their chemical synthesis was described recently by one of us [4-7] and by others [8,9]. Unlike 25-OH-D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub>, which act on gut and bone [10,11], the two other metabolites of cholecalciferol appeared to have a more selective activity. In vitamin D-deficient rats 24,25- and 25,26(OH)<sub>2</sub>D<sub>3</sub>-induced a stimulation of intestinal calcium transport but not of bone calcium mobilization [9,12]. Under slightly different conditions, however, larger doses of both metabolites caused an increase in bone resorption [13].

This apparent contradiction led us to investigate the action of 24,25- and 25,26(OH)<sub>2</sub>D<sub>3</sub> on bone resorption using a mouse bone culture system [14] and to establish the log-dose response curve of doses up to 600 ng/ml in terms of calcium, phosphate and hydroxy-proline release.

## 2. Methods

24,25(OH)<sub>2</sub>D<sub>3</sub>: The metabolite was prepared by

chemical synthesis as described elsewhere [4,6]. The compound is a mixture of diastereoisomers 24 R and 24 S in approximately equal proportions.

25,26(OH)<sub>2</sub>D<sub>3</sub>: The compound was prepared by chemical synthesis as described before [5,7] and consisted of a mixture of diastereoisomers 25 R and 25 S in approximately equal proportions.

Bone culture: The methods are those described previously [14]. The calvaria from 5- to 7-day old mice are cultured in BGJ<sub>b</sub> medium supplemented with 15% horse serum. After a 24 h equilibration period at 37°C in an atmosphere of 5% CO<sub>2</sub> 95% air, the medium is replaced by fresh medium, 2 ml/culture, which in the test vessels contain 25-OHD<sub>3</sub>, 24,25(OH)<sub>2</sub>D<sub>3</sub> or 25,26(OH)<sub>2</sub>D<sub>3</sub>. The vitamin D metabolites are added to the culture medium dissolved in spectroscopic ethanol (0.01 µl/2 ml medium). Each experiment contains a control, a high and low dose of 25-OHD<sub>3</sub> and at least 3 doses of 24,25(OH)<sub>2</sub>D<sub>3</sub> or 25,26(OH)<sub>2</sub>D<sub>3</sub>. The response to the metabolites is calculated as the mean change in medium calcium (7-10 calvaria) from the 7-10 control calvaria.

## 3. Results

There is a log-linear response in bone resorption to concentrations of 25-OHD<sub>3</sub> between 100 and 500




Fig.1. The log-dose response curves of mouse calvaria in tissue culture to 25-OHD<sub>3</sub> (▲), 25,26(OH)<sub>2</sub>D<sub>3</sub> (●) and 24,25(OH)<sub>2</sub>D<sub>3</sub> (○). The data have been combined from several experiments and are expressed as the mean change in medium calcium, μmoles/ml ± S.E.M., of the treated from the untreated calvaria.

ng/ml (fig.1). The metabolites 25,26(OH)<sub>2</sub>D<sub>3</sub> and 24,25(OH)<sub>2</sub>D<sub>3</sub> give a parallel response but at concentrations above 300 ng/ml (fig.1). A significant ( $p < 0.001$ ) increase, however, in bone resorption was

given by 150 ng/ml of 24,25(OH)<sub>2</sub>D<sub>3</sub> whereas no response was seen with 123 ng/ml of 25,26(OH)<sub>2</sub>D<sub>3</sub>. The change in medium calcium is associated with a corresponding change in medium phosphate ( $r = 0.99$ ,  $p < 0.001$ ) and hydroxyproline ( $r = 0.85$ ,  $p < 0.001$ ) and histology of treated calvaria showed an increase in resorption cavities as compared to control calvaria.

#### 4. Discussion

The present results confirm that 25-OHD<sub>3</sub> at concentrations which are near to those found in human plasma, is very active in stimulating resorption in cultured bone [15,16]. The natural metabolites 24,25(OH)<sub>2</sub>D<sub>3</sub> and 25,26(OH)<sub>2</sub>D<sub>3</sub> present in plasma but at a lower concentration than 25-OHD<sub>3</sub>, are also capable of resorbing bone. Both, however, are less potent than 25-OHD<sub>3</sub>. Reynolds et al. [16] showed that 24,25(OH)<sub>2</sub>D<sub>3</sub> did not resorb bone but concentrations higher than 50 ng/ml were not tested. The

Table 1  
Effects of metabolites of vitamin D<sub>3</sub> on the release of calcium in the medium

Vit. D. metabolite	Concentration (ng/ml)	Change in calcium μmoles/ml (± 1 S.E.M.)				<i>p</i>
		Mean	± S.E.M.	<i>n</i>		
24,25(OH) <sub>2</sub> D <sub>3</sub>	68	0.060	0.064	8		<0.5
	75	0.061	0.054	8		<0.5
	110	0.025	0.043	8		<0.5
	150	0.165	0.022	8		<0.001
	270	0.230	0.065	8		<0.01
	300	0.117	0.042	7		<0.05
	300	0.235	0.066	8		<0.05
	400	0.193	0.037	8		<0.01
	500	0.835	0.095	8		<0.001
	600	0.938	0.071	8		<0.001
25,26(OH) <sub>2</sub> D <sub>3</sub>	50	0.119	0.060	7		<0.1
	100	0.020	0.043	8		<0.5
	123	0.072	0.014	8		<0.1
	300	0.269	0.077	7		<0.01
	400	0.533	0.078	8		<0.001
	518	0.905	0.064	8		<0.001
25-OHD <sub>3</sub>	100	0.237	0.030	39		<0.001
	500	1.445	0.054	40		<0.001

*p* The *p* values give the significance of the difference from the controls (Students' *t* - test).

hydroxyl group at the 25 position is important in the bone resorbing activity of vitamin D. So far we have found no vitamin D analogue with a 25 hydroxyl group which is unable to resorb cultured bone (personal data). It is clear, however, that hydroxylation at other sites can decrease or increase the bone resorbing activity.

### Acknowledgement

The 25-OHD<sub>3</sub> was a gift of Roussel UCLAF, Paris.

### References

- [1] Suda, T., Deluca, H. F., Schnoes, H. K., Tanaka, Y. and Holick, M. F. (1970) *Biochemistry* 9, 4776–4780.
- [2] Suda, T., Deluca, H. F., Schnoes, H. K., Ponchon, G., Tanaka, Y. and Holick, M. F. (1970) *Biochemistry* 9, 2917–2922.
- [3] Holick, M. F., Schnoes, H. K., Deluca, H. F., Gray, R. W., Boyle, I. T. and Suda, T. (1972) *Biochemistry* 11, 4251–4255.
- [4] Redel, J., Bell, P. A., Delbarre, F. and Kodicek, E. (1973) *Ct. Rd. hebd. Seanc. Acad. Sci. Paris*, 276 D, 2907–2910.
- [5] Redel, J., Bell, P. A., Delbarre, F. and Kodicek, E. (1974) *Ct. Rd. hebd. Seanc. Acad. Sci. Paris*, 278 D, 529–531.
- [6] Redel, J., Bell, P. A., Bazely, N., Calando, Y., Delbarre, F. and Kodicek, E. (1974) *Steroids* 24, 463–475.
- [7] Redel, J., Bell, P. A., Bazely, N., Calando, Y., Delbarre, F. and Kodicek, E. (1975) *J. Steroid Biochem.* 6, 117–119.
- [8] Lam, H.-Y., Schnoes, H. K., Deluca, H. F. and Chen, T. C. (1973) *Biochemistry* 12, 4851–4855.
- [9] Lam, H.-Y., Schnoes, H. K. and Deluca, H. F. (1975) *Steroids* 25, 247–256.
- [10] Blunt, J. W., Tanaka, Y. and Deluca, H. F. (1968) *Proc. Nat. Acad. Sci. USA* 61, 1503–1506.
- [11] Omdahl, J. L. and Deluca, H. F. (1973) *Physiol. Rev.* 53, 327–372.
- [12] Boyle, I. T., Omdahl, J. L., Gray, R. W. and Deluca, H. F. (1973) *J. Biol. Chem.* 248, 4174–4180.
- [13] Milhaud, G., Labat, M. L. and Redel, J. (1974) *Ct. Rd. Hebd. Acad. Sci. Paris*, 279 D, 827–830.
- [14] Webster, L. A., Atkins, D. and Peacock, M. (1974) *J. Endocr.* 62, 631–637.
- [15] Atkins, D. and Peacock, M. (1974) *J. Endocr.* 61, LXXIX–LXXX.
- [16] Reynolds, J. J., Holick, M. F. and Deluca, H. F. (1974) *Calc. Tiss. Res.* 15, 333–339.